Summary

Location
at UCLA UCSD UCSF
Dates
study started
completion around
Principal Investigator
by Sarah Larson (ucla)

Description

Summary

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study.

Participants who received at least one GM T cell infusion will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

Official Title

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

Keywords

Neoplasms, Long-term follow up, Gene-Modified T Cells, CAR T Cell, Gene-modified (GM) T cell therapy

Eligibility

Locations

Lead Scientist at University of California Health

  • Sarah Larson (ucla)
    HS Associate Clinical Professor, Medicine. Authored (or co-authored) 20 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Celgene
Links
BMS Clinical Trial Information
ID
NCT03435796
Phase
Phase 2/3 Neoplasms Research Study
Study Type
Interventional
Participants
Expecting 317 study participants
Last Updated